{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:45Z","timestamp":1787960205083,"version":"build-2784847793"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Whether prolonged dual antiplatelet therapy (DAPT) is more protective in patients with CKD and drug-eluting stents compared with shorter DAPT is uncertain. The purpose of this meta-analysis was to examine whether shorter DAPT in patients with drug-eluting stents and CKD is associated with lower mortality or major adverse cardiovascular event rates compared with longer DAPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>A Medline literature research was conducted to identify randomized trials in patients with drug-eluting stents comparing different DAPT duration strategies. Inclusion of patients with CKD was also required. The primary outcome was a composite of all-cause mortality, myocardial infarction, stroke, or stent thrombosis (definite or probable). Major bleeding was the secondary outcome. The risk ratio (RR) was estimated using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five randomized trials were included (1902 patients with CKD). Short DAPT (\u22646 months) was associated with a similar incidence of the primary outcome, compared with 12-month DAPT among patients with CKD (48 versus 50 events; RR, 0.93; 95% confidence interval [95% CI], 0.64 to 1.36;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.72). Twelve-month DAPT was also associated with a similar incidence of the primary outcome compared with extended DAPT (\u226530 months) in the CKD subgroup (35 versus 35 events; RR, 1.04; 95% CI, 0.67 to 1.62;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.87). Numerically lower major bleeding event rates were detected with shorter versus 12-month DAPT (9 versus 13 events; RR, 0.69; 95% CI, 0.30 to 1.60;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.39) and 12-month versus extended DAPT (9 versus 12 events; RR, 0.83; 95% CI, 0.35 to 1.93;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.66) in patients with CKD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short DAPT does not appear to be inferior to longer DAPT in patients with CKD and drug-eluting stents. Because of imprecision in estimates (few events and wide confidence intervals), no definite conclusions can be drawn with respect to stent thrombosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.12901018","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T12:59:09Z","timestamp":1555937949000},"page":"810-822","source":"Crossref","is-referenced-by-count":30,"title":["Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents"],"prefix":"10.2215","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-247X","authenticated-orcid":false,"given":"Thomas A.","family":"Mavrakanas","sequence":"first","affiliation":[{"name":"Renal Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts;"},{"name":"Department of Medicine, Geneva University Hospitals, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis S.","family":"Chatzizisis","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Gariani","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Kereiakes","sequence":"additional","affiliation":[{"name":"The Christ Hospital Heart and Vascular Center and The Lindner Center for Research and Education, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland;"},{"name":"Department of Advanced Biomedical Sciences, University Federico II of Naples, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Helft","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, University Hospitals Piti\u00e9-Salp\u00eatri\u00e8re- Charles Foix (Public Assistance- Hospitals of Paris), Sorbonne University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Gilard","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Regional University Hospital La Cavale Blanche, Brest, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Feres","sequence":"additional","affiliation":[{"name":"Institute Dante Pazzanese de Cardiologia, Sao Paulo, Sao Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo A.","family":"Costa","sequence":"additional","affiliation":[{"name":"Institute Dante Pazzanese de Cardiologia, Sao Paulo, Sao Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Morice","sequence":"additional","affiliation":[{"name":"Private Hospital Jacques Cartier, Ramsay G\u00e9n\u00e9rale de Sant\u00e9, Massy, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Georges","sequence":"additional","affiliation":[{"name":"Hospital of Versailles, Le Chesnay, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Charytan","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts;"},{"name":"Baim Institute for Clinical Research, Boston, Massachusetts; and"},{"name":"Division of Nephrology, New York University Langone Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,4,22]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet agents for the treatment and prevention of coronary atherothrombosis.","volume":"70","author":"Patrono","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial.","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"B3-20230813","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial.","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The randomized, multicenter ITALIC trial.","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"B6-20230813","first-page":"365","article-title":"Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: The OPTIDUAL randomized trial.","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): A randomised trial.","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: The SECURITY randomized clinical trial.","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: A randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: A randomized, controlled trial.","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"e003145","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: Randomized substudy of the I-LOVE-IT 2 trial.","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-Month versus 12-Month dual-antiplatelet therapy following long everolimus-eluting stent implantation: The IVUS-XPL Randomized Clinical Trial.","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: A pairwise and Bayesian network meta-analysis of randomised trials.","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: A systematic review and meta-analysis of randomized controlled trials.","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4244\/EIJ-D-17-00468","article-title":"State of the art: Duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives.","volume":"13","author":"Gargiulo","year":"2017","journal-title":"EuroIntervention"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamacardio.2016.2110","article-title":"Antiplatelet therapy for long-term secondary prevention after myocardial infarction.","volume":"1","author":"Bonaca","year":"2016","journal-title":"JAMA Cardiol"},{"key":"B20-20230813","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: A collaborative meta-analysis of randomized trials.","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention.","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ccd.26921","article-title":"Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial.","volume":"90","author":"Gargiulo","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with CKD.","volume":"27","author":"Molnar","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","article-title":"Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: A systematic review and meta-analysis.","volume":"156","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting.","volume":"69","author":"Palmerini","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamacardio.2017.0063","article-title":"Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting:A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) study.","volume":"2","author":"Secemsky","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2215\/CJN.04430416","article-title":"Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis.","volume":"12","author":"Chen","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","article-title":"Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).","volume":"103","author":"Dasgupta","year":"2009","journal-title":"Am J Cardiol"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1161\/CIRCULATIONAHA.110.974683","article-title":"Ticagrelor in the renal dysfunction subgroup: Subjugated or substantiated?","volume":"122","author":"Montalescot","year":"2010","journal-title":"Circulation"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"784.e1","DOI":"10.1016\/j.ahj.2009.08.013","article-title":"The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy.","volume":"158","author":"Singla","year":"2009","journal-title":"Am Heart J"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","article-title":"Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized Dual Antiplatelet Therapy study.","volume":"133","author":"Meredith","year":"2016","journal-title":"Circulation"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacc.2008.05.054","article-title":"Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel.","volume":"52","author":"Ang","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.117.028497","article-title":"It is time to end the dualistic short versus long duration of dual antiplatelet therapy debates.","volume":"135","author":"Levine","year":"2017","journal-title":"Circulation"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention.","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: Risk scores from PARIS.","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials.","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacc.2017.12.004","article-title":"Clash of oral P2Y12 receptor inhibitors in acute coronary syndromes.","volume":"71","author":"Chatzizisis","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B46-20230813","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial.","volume":"37","author":"Magnani","year":"2016","journal-title":"Eur Heart J"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.kint.2016.09.014","article-title":"Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.","volume":"91","author":"Carrero","year":"2017","journal-title":"Kidney Int"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/09537104.2017.1316485","article-title":"Platelet reactivity in stable cardiovascular patients with chronic kidney disease.","volume":"29","author":"Mavrakanas","year":"2018","journal-title":"Platelets"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"f6530","DOI":"10.1136\/bmj.f6530","article-title":"Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: Comprehensive network meta-analysis.","volume":"347","author":"Navarese","year":"2013","journal-title":"BMJ"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201906000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:38:31Z","timestamp":1786369111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201906000-00008"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2019,4,22]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12901018","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,22]]}}}